Smithers Pharmaceutical Development Services to Present at the 3rd Global Cell & Gene Therapy Summit
Smithers Pharmaceutical Development Services will attend the 3rd Global Cell & Gene Therapy Summit at the Four Points by Sheraton Wakefield Boston Hotel & Conference Center from July 6–8, 2026. Hosted by United Scientific Group, the event will bring together biotechnology companies, pharmaceutical developers, regulatory professionals, and scientific leaders focused on advancing cell and gene therapy development.
Representing Smithers Pharmaceutical Development Services throughout the conference will be Connie Scott and Agostinho G. Rocha. Both executives will be available to host meetings at Exhibit 1 during the event.
Strategic Molecular Bioanalysis to Accelerate Cell and Gene Therapy Development
Agostinho G. Rocha, PhD, will present “Strategic Molecular Bioanalysis to Accelerate Cell and Gene Therapy Development,” a session focused on how early bioanalytical planning can reduce development risk, improve operational efficiency, and accelerate timelines for emerging cell and gene therapy programs.
Many biotechnology organizations entering clinical development operate without dedicated in-house bioanalytical departments. As a result, assay strategy, validation timing, and regulatory planning decisions are often made under compressed timelines. Delayed planning can increase development risk, create avoidable rework, and slow program progression.
Smithers Pharmaceutical Development Services will discuss how proactive molecular bioanalysis strategies can support more efficient program execution across complex therapeutic pipelines.
The presentation will address key areas of molecular bioanalysis required throughout cell and gene therapy development, including biodistribution studies, persistence analysis, vector shedding, transgene expression assessment, vector copy number determination, and cellular kinetics support for cell therapy programs.
Supporting Biotech Companies Through Complex Development Milestones
Cell and gene therapy programs require specialized analytical approaches that align with evolving scientific and regulatory expectations. Emerging biotechnology companies are frequently tasked with balancing development speed, technical accuracy, operational efficiency, and budget considerations while advancing toward clinical milestones.
Smithers Pharmaceutical Development Services supports sponsors with molecular bioanalytical expertise designed to reduce unnecessary trial-and-error development processes. Early collaboration and strategic assay planning can help sponsors avoid delays that impact validation activities, clinical readiness, and downstream regulatory submissions.
The session will highlight how experienced scientific partnerships can improve decision-making during critical stages of development and help programs move more efficiently from analytical strategy to clinical execution.
Designed for Executive and Scientific Decision Makers
The presentation is intended for executive leaders, directors, and scientific decision makers responsible for managing bioanalytical strategy within cell and gene therapy programs.
Attendees involved in translational development, clinical operations, regulatory planning, and outsourced analytical management will gain insight into approaches that can strengthen development efficiency and reduce program risk.
The summit also provides an opportunity for biotechnology organizations to engage directly with Smithers Pharmaceutical Development Services leadership regarding current and future development needs.
Schedule a Meeting with Smithers Pharmaceutical Development Services
Organizations attending the 3rd Global Cell & Gene Therapy Summit are encouraged to schedule meetings with Smithers Pharmaceutical Development Services in advance of the conference.
Connie Scott and Agostinho G. Rocha, PhD, will be available throughout the event at Exhibit 1 to discuss molecular bioanalysis strategy, assay development, validation planning, and broader support for cell and gene therapy programs.
